{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-26-000034","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2026-06-11T11:06:57+00:00","discovered_at":"2026-06-11T11:10:00.215702+00:00","generated_at":"2026-06-11T11:10:10.279198+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nurix reports Phase 1a/1b data for bexobrutideg: ORR 83% in R/R CLL, 92.9% in earlier-line","bullets":["Phase 1a ORR 83.0% (47 evaluable), median PFS 22.1 months; median 4 prior lines.","Phase 1b Cohort 5 (BTKi-treated, BCL2i-naïve): ORR 92.9% at 5.2 months follow-up; 18/19 on treatment.","Phase 1b Cohort 15 (BTKi-naïve, incl. treatment-naïve): ORR 84.2% at 4.9 months; 19/20 on treatment.","Safety: well-tolerated, no dose-limiting toxicities, no treatment-related Grade 5 events; AE discontinuation 5.6%.","Company plans Phase 3 monotherapy program and has Roche collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-26-000034","json":"https://secwatch.observer/filing/0001549595-26-000034.json","markdown":"https://secwatch.observer/filing/0001549595-26-000034.md","text":"https://secwatch.observer/filing/0001549595-26-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000034/0001549595-26-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000034/nrix-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:10:10.279198+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}